Avantax Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $541K | Buy |
11,115
+464
| +4% | +$22.6K | ﹤0.01% | 1543 |
|
|
2025
Q1 | $362K | Buy |
10,651
+3,815
| +56% | +$130K | ﹤0.01% | 1705 |
|
|
2024
Q4 | $269K | Buy |
+6,836
| New | +$269K | ﹤0.01% | 1856 |
|
|
2024
Q3 | – | Sell |
-4,324
| Closed | -$234K | – | 2136 |
|
|
2024
Q2 | $234K | Sell |
4,324
-463
| -10% | -$25K | ﹤0.01% | 1861 |
|
|
2024
Q1 | $326K | Sell |
4,787
-661
| -12% | -$45.1K | ﹤0.01% | 1252 |
|
|
2023
Q4 | $341K | Buy |
+5,448
| New | +$341K | ﹤0.01% | 1170 |
|
|
2023
Q1 | – | Sell |
-7,503
| Closed | -$305K | – | 1493 |
|
|
2022
Q4 | $305K | Buy |
7,503
+952
| +15% | +$38.7K | ﹤0.01% | 1098 |
|
|
2022
Q3 | $428K | Buy |
6,551
+117
| +2% | +$7.64K | 0.01% | 842 |
|
|
2022
Q2 | $391K | Buy |
6,434
+1,057
| +20% | +$64.2K | 0.01% | 885 |
|
|
2022
Q1 | $344K | Buy |
5,377
+779
| +17% | +$49.8K | ﹤0.01% | 941 |
|
|
2021
Q4 | $348K | Buy |
4,598
+178
| +4% | +$13.5K | 0.01% | 905 |
|
|
2021
Q3 | $494K | Buy |
4,420
+597
| +16% | +$66.7K | 0.01% | 727 |
|
|
2021
Q2 | $620K | Buy |
3,823
+1,684
| +79% | +$273K | 0.01% | 621 |
|
|
2021
Q1 | $260K | Buy |
+2,139
| New | +$260K | 0.01% | 869 |
|